Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
61.8M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
38.8M
-
Shares change
-
-1.17M
-
Total reported value, excl. options
-
$375M
-
Value change
-
-$12M
-
Number of buys
-
30
-
Number of sells
-
-19
-
Price
-
$9.67
Significant Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) as of Q2 2022
59 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.8M shares
of 61.8M outstanding shares and own 62.72% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.7M shares), FMR LLC (6.21M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.25M shares), BlackRock Inc. (3.31M shares), Avoro Capital Advisors LLC (3.31M shares), Cormorant Asset Management, LP (2.99M shares), VANGUARD GROUP INC (2.26M shares), Aisling Capital Management LP (1.47M shares), Alphabet Inc. (1.46M shares), and RTW INVESTMENTS, LP (1.21M shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.